Another approach taken by the same research group was to provide 4-1BB co-stimulation alongside PD-1 blockade, which led to increased CD8+ T cell mitochondrial capacity and a favorable antitumor response, again in an experimental melanoma model (Menk et al., 2018). The gene discussed is CD8A; the disease is melanoma.